Discover. Innovate. Deliver.

BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.

Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn


BrainStorm is dedicated to defeating neurodegenerative diseases using an innovative, best-in-class, autologous cellular therapeutic technology platform, termed NurOwn®.


Play Video

BrainStorm’s autologous MSC-NTF cell therapy is investigational and not FDA approved.

Defining a new class of autologous cellular therapeutics

Grounded in breakthrough scientific innovation and focused on unmet medical need, BrainStorm is building a best-in-class platform, NurOwn®, for production of commercial-ready MSC-NTF cells to treat highly debilitating neurodegenerative diseases that currently have limited treatment options.


BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage, biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases.

BrainStorm’s autologous MSC-NTF cell therapy has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in amyotrophic lateral sclerosis (ALS) and has additionally been granted Orphan Status by the U.S. FDA and the European Medicines Agency (EMA).

BrainStorm has completed a phase 3 pivotal trial using repeat-administration of autologous MSC-NTF cells in ALS in the United States. 

BrainStorm has completed a phase 2 study of autologous MSC-NTF cells in patients with progressive multiple sclerosis (MS). Learn more.

Scroll to Top